Open Access Case study

A Rare Case Report of a Metastatic Tumor of the Spermatic Cord Arising from Pancreatic Cancer

Ryuta Sato, Dai Watanabe, Masaharu Imagawa, Masahiro Okamoto, Kengo Fukuzawa, Hirotoshi Yonemasu

Journal of Cancer and Tumor International, Page 1-4
DOI: 10.9734/JCTI/2017/35465

A 60-year-old patient complaining of pain and elevation of the right scrotal contents, who had been treated for pancreatic cancer, was suspected of having spermatic cord tumor. He underwent high orchiectomy for pain management and pathological diagnosis. The tumor was a metastatic adenocarcinoma from pancreatic cancer. Pancreatic cancer accompanied by spermatic cord metastasis is extremely rare. In patients with a mass in the spermatic cord and a history of neoplasm, the possibility of metastasis from the primary cancer should be considered.

 

Open Access Original Research Article

Symptoms Burden, Quality of Life and Its Determinant Factors in Advanced Lung Cancer Patients

Asma Ammar, Mariem Dhahri, Iheb Bougmiza, Rim Chafai, Faten Ezzairi, Mansour Njah, Nabiha Bouafia

Journal of Cancer and Tumor International, Page 1-10
DOI: 10.9734/JCTI/2017/35636

Aims: To assess in advanced lung cancer patients’, reported symptoms burden, their QOL, and to identify determinant factors associated with their QOL in 2 healthcare departments.

Study Design: A cross sectional study.

Place and Duration of the Study: The study was carried out during 03 months from February 1st to 30 April 2016 in the Pneumology department and an oncology unit from 2 different University Hospitals in Tunisia.

Methodolgy: We recruited 60 patients with advanced lung cancer by convenience sampling.             QOL was assessed by the SF-36 questionnaire and Symptom’s burden by Lung Cancer           Symptom Scale (LCSS).

Results: The mean LCSS score was 43.07 (SD, 21.45). Loss of appetite and fatigue were rated as the most severe symptoms. The mean overall score of SF36 was 39.3 (SD, 15.4). The physical and emotional limitations had the lowest scores.

Unemployment (p<0.014), smoking cessation after diagnosis (p<0.013), consumption of analgesic (p<0.002) and the indication of an analgesic radiotherapy (p<0.001) were revealed as independent determinants of QOL.

Conclusion: A built in support of lung cancer patients would better control the symptoms and promote their QOL.

 

Open Access Original Research Article

Evaluation of Efficacy of Gefinitib in Comparison with Chemotherapy in Patients with Non-Small Cell Lung Carcinoma from India

Shyam Aggarwal, Sachin Minhas, Mayank Jauhri, Yogender Shokeen, Madhusudan Ganvir, Manish Pungliya, C. T. Sateesh, H. P. Shashidhara, Shekar Patil

Journal of Cancer and Tumor International, Page 1-7
DOI: 10.9734/JCTI/2017/35710

Aim: Tyrosine kinase inhibitors (TKIs) are a new class of drugs that are proven to be more efficacious than chemotherapy in certain cancers including lung cancer. However, the efficacy of TKIs may vary in different global populations as different ethnic populations have different genetic and/or environmental background. In this study, we have evaluated the efficacy of gefinitib in comparison with chemotherapy in patients with non-small cell lung carcinoma (NSCLC) from India. Methods: 50 Non-smokers or ex-light-smokers patients with histologically proven diagnosis of NSCLC were included in this study. 28 patients were positive for EGFR mutations and 18 patients negative for EGFR mutations. We compared the response rates and overall survival of EGFR mutation positive patients and EGFR mutation negative patients with respect to the gefitinib treatment. The statistical significance was calculated using Chi-square test. 

Results: The overall response rate in patients with EGFR mutation-positive tumors treated with gefitinib was found to be 67% as compared to only 12.5% in case of EGFR mutation negative patients treated with gefitinib. The overall survival rate was found to be better in patients who were EGFR positive (15.58±6.39 months) as compared to patients who were EGFR negative (6.63±5.78 months), when treated upfront with gefitinib (p=0.005).

Conclusion: In conclusion, the results of the present study demonstrate that Indian NSCLC patients who were EGFR positive respond favorably to gefitinib and it may be considered as a more suitable option, in comparison to chemotherapy, for the treatment of NSCLC Indian patients who are EGFR mutation positive.

 

Open Access Original Research Article

Do pathologists thoroughly Evaluate the Greater Omentum Following Gastrectomy for Malignancy: an Audit Based on Histopathology Reports

O. Tobiko, J. Kiluba, C. Jann-Kruger, M. J. Hale, T. E. Luvhengo

Journal of Cancer and Tumor International, Page 1-8
DOI: 10.9734/JCTI/2017/35246

Introduction: Milky spots in greater omentum are primary sites for seeding of exfoliated cells from intra-abdominal malignancies. Surgery is the mainstay of treatment of gastric adenocarcinoma and the greater omentum is usually resected en-bloc.  

Aim: To study the histopathological profile of gastric malignancies and to determine if pathologists routinely analyze the greater omentum submitted following gastrectomy.  

Methods: An audit of histopathology records of patients who had gastric malignancies between 2008 and 2012 was undertaken. Data retrieved included patients’ demography, tumour site, tumour histology and subtypes, Helicobacter pylori status, associated gastritis, types of gastrectomy and; analysis and finding of omental deposits.

Results: 325 records were found of which 76.6% were adenocarcinomas. The overall male to female ratio of patients was 192:133 and their average age overall was 59.0 years (range: 23102 years). The average age of patients who had adenocarcinoma was 60.2 years. Around 8.8% of patients who had adenocarcinoma were younger than 40 years.

Gastric resection was performed in 23.1% adenocarcinomas of which 9.1% was stage I based on final histology. The greater omentum was part of specimen in 46.6% cases but report regarding cancer deposits was specified in 25.9% of which 11.1% were positive.

Conclusion: Pathologists do not routinely analyze and report findings on the greater omentum of patients who had gastrectomy for cancer. It potentially leads to under-staging.  Analysis of the greater omentum for cancer cell deposits should be incorporated into the standard pathology reporting template for gastric cancer following curative gastrectomy.  

 

Open Access Original Research Article

Can Calcium and Magnesium Infusion before and after Oxaliplatin Administration Improves Its Neurotoxic Effect?

Mohamed S. Zahi, Hend M. Hamdey Rashed Elkalla

Journal of Cancer and Tumor International, Page 1-7
DOI: 10.9734/JCTI/2017/35988

Introduction: The oxaliplatin neurotoxicity is one of two distinct phases: an acute and a dose-limiting cumulative phase. Large doses of I.V Ca & Mg is given before and after oxaliplatin in FOLFOX protocol.

Aim: We aimed to evaluate the efficacy of Ca & Mg in improving or eliminating oxaliplatin-induced neurotoxicity.

Study Design: Randomized double controlled placebo study.

Place and Duration of Study: Clinical Oncology department at Mansoura university hospital, Egypt at the period from July 2014 up to December 2016 inclusive.  

Methodology: In our study, 140 Patients with adenocarcinoma of the colon received 6 months of FOLFOX protocol. Patients were choiced to receive I.V calcium gluconate plus magnesium sulfate (1 g for both of them) in 100 mL of D5W for about 30 minutes immediately before and after each cycle of oxaliplatin (70 patients ), or an identical looking placebo shortly before and after each cycle of oxaliplatin (70 patients ) in a random manner. The primary end point was a comparison between neurotoxicity assessed by Common Terminology Criteria for Adverse Effects (CTCAE) version 4.0 in both groups.

Results: There was statistically significant difference as regard grade of neuralgia. Grade II neuralgia is higher in the study group II (45.7%) compared to (22.9%) in the study group I. There was statistically significant difference as regard grade of paresthesia. Grade II & III are higher in study group II (51.4%, 14.3%) compared to (30.0%, 4.3%) in study group I.

Conclusion: Ca and Mg administration with oxaliplatin have been well tolerated. Our results support the role of Ca & Mg in decreasing neurotoxicity associated with oxaliplatin.